Safety Profile of Ibrutinib: An Analysis of the WHO Pharmacovigilance Database
As ibrutinib has become a standard of care in B-cell malignancies in monotherapy or in combination with other agents, definition of its safety profile appears essential. The aim of this study was to further characterize the safety profile of ibrutinib through the identification of potential safety s...
Saved in:
Main Authors: | Marion Allouchery (Author), Cécile Tomowiak (Author), Thomas Lombard (Author), Marie-Christine P (Author), Francesco Salvo (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2021-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The reporting of disproportionality analysis in pharmacovigilance: spotlight on the READUS-PV guideline
by: Michele Fusaroli, et al.
Published: (2024) -
Safety Profile of Medicines Used for the Treatment of Drug-Resistant Tuberculosis: A Descriptive Study Based on the WHO Database (VigiBase<sup>®</sup>)
by: Alemayehu Lelisa Duga, et al.
Published: (2023) -
Propensity Score-Based Approaches in High Dimension for Pharmacovigilance Signal Detection: an Empirical Comparison on the French Spontaneous Reporting Database
by: Émeline Courtois, et al.
Published: (2018) -
Cardiovascular Toxicities of Ibrutinib: A Pharmacovigilance Study Based on the United States Food and Drug Administration Adverse Event Reporting System Database
by: Yi Zheng, et al.
Published: (2023) -
Safety profile of tirzepatide: A real-world pharmacovigilance analysis of EudraVigilance database
by: Atul Khurana, et al.
Published: (2024)